Mohamed A. Gouda

The University of Texas MD Anderson Cancer Center

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 5%percentile

0.561Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

The Landscape of Alterations from 1407 Ultra-Rare Sarcomas from the AACR GENIE Database: Clinical Implications

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0876

Top 35%

0.561DataRank

Top 35%8 citations

Justin T. Moyers, Mohamed A. Gouda, Anthony P. Conley, Alexander J. Lazar, Vivek Subbiah +1 more

Papers

Driven by 26 papers — median percentile 65. Top paper: “Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult and Pediatric Solid Tumors”.

Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult and Pediatric Solid Tumors

American Society of Clinical Oncology Educational Book(2023)10.1200/edbk_404770

N/A

2.4DataRank · unranked

95 citations

Vivek Subbiah, Mohamed A. Gouda

Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0090

N/A

1.9DataRank · unranked

60 citations

Blessie Elizabeth Nelson, Lars Buschhorn, Adam Wahida, Vivek Subbiah, Mohamed A. Gouda

A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer

ESMO Open(2025)10.1016/j.esmoop.2025.104536

N/A

0.626DataRank · unranked

64 citations

Martin H. Voss, Hussein A. Tawbi, Michael S. Gordon, Scott S. Tykodi, Elaine T. Lam +13 more

The Landscape of Alterations from 1407 Ultra-Rare Sarcomas from the AACR GENIE Database: Clinical Implications

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0876

Top 35%

0.561DataRank

Top 35%8 citations

Justin T. Moyers, Mohamed A. Gouda, Anthony P. Conley, Alexander J. Lazar, Vivek Subbiah +1 more

Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer

npj Precision Oncology(2024)10.1038/s41698-024-00563-4

N/A

0.494DataRank · unranked

26 citations

Mohamed A. Gouda, J. Bryan Iorgulescu, Ramona Dadu, Keyur Patel, Steven I. Sherman +8 more

Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma

ESMO Open(2021)10.1016/j.esmoop.2021.100357

N/A

0.494DataRank · unranked

26 citations

Jiří Polívka, Hong Huang, I. Treskova, Kristýna Pivovarčíková, T. Fikrle +7 more

Precision oncology with selective RET inhibitor selpercatinib in RET -rearranged cancers

Therapeutic Advances in Medical Oncology(2023)10.1177/17588359231177015

N/A

0.457DataRank · unranked

20 citations

Vivek Subbiah, Mohamed A. Gouda

Predictive Significance of Combined Plasmatic Detection of BRAF Mutations and S100B Tumor Marker in Early‐Stage Malignant Melanoma

Cancer Medicine(2024)10.1002/cam4.70313

N/A

0.330DataRank · unranked

8 citations

Mohamed A. Gouda, Mahyar Sharif Bagheri, Martin Pešta, Helen J. Huang, Inka Třešková +10 more

Precision oncology for biliary tract tumors: it’s written in blood!

Annals of Oncology(2022)10.1016/j.annonc.2022.09.157

N/A

0.312DataRank · unranked

7 citations

Vivek Subbiah, Mohamed A. Gouda

Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study

ESMO Open(2023)10.1016/j.esmoop.2023.101609

N/A

0.256DataRank · unranked

3 citations

X. Wang, Najat C. Daw, C.E. Herzog, Ishwaria M. Subbiah, Wafik Zaky +10 more

Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial

Journal of Immunotherapy and Precision Oncology(2025)10.36401/jipo-24-17

N/A

0.217DataRank · unranked

3 citations

Mohamed A. Gouda, Matthew J. Reilley, Amadeo B. Biter, JoAnn Lim, Stacie A. Bean +15 more

A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma

Cancer Medicine(2025)10.1002/cam4.70280

N/A

0.212DataRank · unranked

3 citations

Mohamed A. Gouda, Denái R. Milton, Hassan Ahmed Momin, Bülent Yılmaz, Bettzy Stephen +16 more

Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3531

N/A

0.208DataRank · unranked

3 citations

Filip Jankú, Ying Yuan, Leylah Drusbosky, Alice P. Chen, Xiaofeng Zheng +15 more

Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma: A Phase 1B Trial

Journal of Immunotherapy and Precision Oncology(2025)10.36401/jipo-24-10

N/A

0.165DataRank · unranked

2 citations

Abdulrazzak Zarifa, Yali Yang, Bettzy Stephen, Serdar A. Gurses, Ashabari Sprenger +6 more

532 A phase 1 dose escalation and dose expansion trial of NP-101 in patients with advanced solid tumors

Regular and Young Investigator Award Abstracts(2025)10.1136/jitc-2025-sitc2025.0532

N/A

0DataRank · unranked

0 citations

Bettzy Stephen, Serdar A. Gurses, Michelle York Gocio, Mohamed Omar Kaseb, Yali Yang +18 more

Exportin(g) precision oncology beyond genomics with XPO1 inhibition

(2022)10.1016/j.medj.2022.10.005

N/A

0DataRank · unranked

0 citations

Vivek Subbiah, Mohamed A. Gouda

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy

ESMO Open(2023)10.1016/j.esmoop.2023.100788

N/A

0DataRank · unranked

103 citations

Vivek Subbiah, Mohamed A. Gouda

N-of-1 Trials in Cancer Drug Development

Cancer Discovery(2023)10.1158/2159-8290.cd-22-1377

N/A

0DataRank · unranked

44 citations

Lars Buschhorn, Andreas Schneeweiß, Adam Wahida, Vivek Subbiah, Mohamed A. Gouda

Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma

npj Precision Oncology(2023)10.1038/s41698-023-00398-5

N/A

0DataRank · unranked

11 citations

Neha K. Reddy, Jason T. Huse, Behrang Amini, Mirella Nardo, Mohamed A. Gouda +3 more

Weight gain in patients with RET aberrant cancers treated with brain penetrant RET selective inhibitors

Annals of Oncology(2023)10.1016/j.annonc.2023.07.002

N/A

0DataRank · unranked

7 citations

Mimi I. Hu, Maria E. Cabanillas, Jie Wu, Funda Meric‐Bernstam, Vivek Subbiah +1 more

Sodium fluoride (Na18F) PET Response Criteria in Solid Tumors (NAFCIST): a framework for response assessment in bone tumors

ESMO Open(2023)10.1016/j.esmoop.2023.101575

N/A

0DataRank · unranked

2 citations

Mohamed A. Gouda, Lars Buschhorn, Adam Wahida, Homer A. Macapinlac, Peter M. Anderson +2 more

Multi-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation with the switch-control kinase inhibitor ripretinib and surgery`

Oncoscience(2023)10.18632/oncoscience.586

N/A

0DataRank · unranked

2 citations

Filip Jankú, Neeta Somaiah, Kelly K. Hunt, Sireesha Yedururi, Vivek Subbiah +1 more

Activity of pazopanib in EWSR1-NFATC2 translocation-associated bone sarcoma

Oncoscience(2023)10.18632/oncoscience.587

N/A

0DataRank · unranked

2 citations

Maria A. Zarzour, Ara A. Vaporciyan, Kalevi Kairemo, Hubert H. Chuang, Vivek Subbiah +1 more

Learning From Mistakes: Navigating Medical Errors in Oncology From Prevention to Management

Journal of Immunotherapy and Precision Oncology(2024)10.36401/jipo-24-21

N/A

0DataRank · unranked

0 citations

Jessica Osburn, Mohamed A. Gouda, Daniel D. Karp

Selpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor model

Cancer Letters(2025)10.1016/j.canlet.2025.217444

N/A

0DataRank · unranked

3 citations

Mohamed A. Gouda, Shriya Pandey, Neeraj Chauhan, Tao Shen, Xueqing Hu +5 more

Prolonged response to dual immune checkpoint blockade in patients with advanced solid tumors: a case series

npj Precision Oncology(2025)10.1038/s41698-025-01115-0

N/A

0DataRank · unranked

0 citations

Mohamed A. Gouda, Apostolia M. Tsimberidou, Camila Bragança Xavier

Mohamed A. Gouda

Indexed papers

Top data-sharing exemplar

Papers